Evogene (EVGN) CEO Haviv Ofer details multi-year stock option grants
Rhea-AI Filing Summary
Evogene Ltd. director and President & CEO Haviv Ofer filed an initial ownership report showing he holds stock options over ordinary shares in the company. These include options over 22,500 shares at an exercise price of 51.9600 per share expiring on August 8, 2027, 50,000 shares at 10.5000 per share expiring on April 21, 2030, and 52,800 shares at 1.6600 per share expiring on December 23, 2034. A footnote explains that the options granted on December 23, 2024 vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal quarterly installments of 6.25% over the next twelve quarters.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Haviv Ofer
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy ordinary shares) — 125,300 shares (Direct)
Footnotes (1)
- F1. The options reported in this row vest and become exercisable over a period of four years from the December 23, 2024 grant date. 25% of the options vested and became exercisable upon the one-year anniversary of the grant date and the remainder of the options vest and become exercisable equally on a quarterly basis (6.25% per quarter) over the following twelve quarters such that all options will be fully vested and exercisable on the four-year anniversary of the grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Evogene (EVGN) CEO Haviv Ofer report on this Form 3?
He reports his initial beneficial ownership in Evogene through stock options. The filing lists three direct option positions over ordinary shares, each with a specific exercise price, expiration date, and underlying share amount, establishing his disclosed equity-based compensation holdings.
What are the exercise prices of Haviv Ofer’s Evogene stock options?
He holds stock options with exercise prices of 51.9600, 10.5000, and 1.6600 per ordinary share. Each option series is reported with its own terms, including the number of underlying shares and the respective expiration dates disclosed in the filing.
When do Haviv Ofer’s Evogene stock options expire?
The reported stock options expire on August 8, 2027, April 21, 2030, and December 23, 2034. Each expiration date corresponds to a distinct grant, with its own exercise price and underlying ordinary share amount disclosed as part of his derivative holdings.
How do the December 23, 2024 Evogene options granted to Haviv Ofer vest?
According to the footnote, those options vest over four years from the December 23, 2024 grant date. Twenty-five percent vest after one year, and the remaining options vest in equal quarterly installments of 6.25% over the following twelve quarters until fully vested.
Are Haviv Ofer’s Evogene stock options held directly or indirectly?
The filing characterizes these option positions as directly owned. Each line in the transaction and derivative summaries identifies the ownership type as direct, indicating the options are attributed personally to him rather than to an intermediary entity or related party.